No Evidence of BCMA Expression Loss or Systemic Immune Impairment after Treatment with the BCMA-Targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
| Autor: | Daniel E. Lowther, E. Andres Houseman, Gang Han, Eleni Kleanthous, Dawson Knoblock, Xiangdong Zhou, Shreyan Banerjee, Sagar Patel, David Figueroa |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Blood. 140:611-613 |
| ISSN: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood-2022-157767 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|